
Cancer Biologics Market
Cancer Biologics Market - Global Industry Assessment & Forecast
Segments Covered
By Drug Class Monoclonal Antibodies, Cancer Growth Inhibitors, Vaccines, Recombinants Proteins , CAR-T Cells, Angiogenesis Inhibitors, Interleukins (IL), Interferons (IFN), Gene Therapy, Other Drug Classes
By Application Blood Cancer, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Gastric Cancer, Ovarian Cancer, Skin Cancer, Liver Cancer, Other Applications
By End Use Hospitals, Cancer Center, Academics & Research Institutes
By Region North America , Europe , Asia Pacific, Latin America, Middle East & Africa
Snapshot
![]() |
2023 |
![]() |
2024 - 2032 |
![]() |
2018 - 2022 |
![]() |
USD 109.1 Billion |
![]() |
USD 197.1 Billion |
![]() |
6.79% |
![]() |
Asia Pacific |
![]() |
North America |
Customization Offered
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market Dynamics
Region Level Market Share
Import Export Analysis
Production Analysis
Others Request Customization Speak To Analyst
Cancer Biologics Market Segment Analysis
- Cancer Biologics Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- Cancer Biologics Application Outlook (Revenue, USD Million, 2018 - 2030)
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- Cancer Biologics End Use Outlook (Revenue, USD Million, 2018 - 2030)
- Hospitals
- Cancer Center
- Academics & Research Institutes
-
Regional Outlook (Revenue, USD Billion/Million, 2018 - 2030)
- North America
-
North America Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
-
North America Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
-
North America Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- U.S.
- U.S. Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- U.S. Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- U.S. Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- U.S. Cancer Biologics Market, by Drug Class
- Canada
- Canada Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- Canada Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- Canada Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- Canada Cancer Biologics Market, by Drug Class
-
Mexico
- Mexico Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- Mexico Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- Mexico Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- Mexico Cancer Biologics Market, by Drug Class
-
North America Cancer Biologics Market, by Drug Class
- Europe
-
Europe Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
-
Europe Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
-
Europe Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- U. K.
- U.K. Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- U.K. Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- U.K. Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- U.K. Cancer Biologics Market, by Drug Class
- France
- France Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- France Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- France Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- France Cancer Biologics Market, by Drug Class
-
Germany
- Germany Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- Germany Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- Germany Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- Germany Cancer Biologics Market, by Drug Class
-
Italy
- Italy Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- Italy Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- Italy Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- Italy Cancer Biologics Market, by Drug Class
-
Spain
- Spain Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- Spain Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- Spain Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- Spain Cancer Biologics Market, by Drug Class
-
Rest of Europe
- Rest of Europe Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- Rest of Europe Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- Rest of Europe Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- Rest of Europe Cancer Biologics Market, by Drug Class
-
Europe Cancer Biologics Market, by Drug Class
- Asia Pacific
-
Asia Pacific Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
-
Asia Pacific Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
-
Asia Pacific Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- China
- China Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- China Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- China Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- China Cancer Biologics Market, by Drug Class
- Japan
- Japan Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- Japan Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- Japan Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- Japan Cancer Biologics Market, by Drug Class
-
Germany
- Germany Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- Germany Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- Germany Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- Germany Cancer Biologics Market, by Drug Class
-
India
- India Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- India Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- India Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- India Cancer Biologics Market, by Drug Class
-
South Korea
- South Korea Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- South Korea Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- South Korea Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- South Korea Cancer Biologics Market, by Drug Class
-
South East Asia
- South East Asia Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- South East Asia Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- South East Asia Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- South East Asia Cancer Biologics Market, by Drug Class
-
Rest of Asia Pacific
- Rest of Asia Pacific Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- Rest of Asia Pacific Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- Rest of Asia Pacific Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- Rest of Asia Pacific Cancer Biologics Market, by Drug Class
-
Asia Pacific Cancer Biologics Market, by Drug Class
- Latin America
-
Latin America Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
-
Latin America Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
-
Latin America Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- Brazil
- Brazil Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- Brazil Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- Brazil Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- Brazil Cancer Biologics Market, by Drug Class
- Argentina
- Argentina Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- Argentina Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- Argentina Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- Argentina Cancer Biologics Market, by Drug Class
-
Rest of Latin America
- Rest of Latin America Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- Rest of Latin America Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- Rest of Latin America Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- Rest of Latin America Cancer Biologics Market, by Drug Class
-
Latin America Cancer Biologics Market, by Drug Class
- Middle East & Africa
-
Middle East & Africa Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
-
Middle East & Africa Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
-
Middle East & Africa Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- GCC Countries
- GCC Countries Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- GCC Countries Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- GCC Countries Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- GCC Countries Cancer Biologics Market, by Drug Class
- South Africa
- South Africa Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- South Africa Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- South Africa Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- South Africa Cancer Biologics Market, by Drug Class
-
Rest of Middle East & Africa
- Rest of Middle East & Africa Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- Rest of Middle East & Africa Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- Rest of Middle East & Africa Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- Rest of Middle East & Africa Cancer Biologics Market, by Drug Class
-
Middle East & Africa Cancer Biologics Market, by Drug Class
- North America

FAQ
Frequently Asked Question
What is the global demand for Cancer Biologics in terms of revenue?
-
The global Cancer Biologics valued at USD 109.1 Billion in 2023 and is expected to reach USD 197.1 Billion in 2032 growing at a CAGR of 6.79%.
Which are the prominent players in the market?
-
The prominent players in the market are Abbott Laboratories (U.S.), Angel Pharmaceuticals (China), Amgen Inc. (U.S.), AstraZeneca (UK), BioNTech (Germany), Bristol-Mayer Squibb Company (U.S.), Dr. Reddy's Laboratories (India), Duality Biologics (China), Eli Lilly and Company (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland).
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 6.79% between 2024 and 2032.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Cancer Biologics include
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Cancer Biologics in 2023.